Merck (MRK), ARIAD (ARIA) Issue Statement Following FDA Panel Decision on Ridaforolimus
Go back to Merck (MRK), ARIAD (ARIA) Issue Statement Following FDA Panel Decision on Ridaforolimus| Ariad Pharmaceuticals, Inc. (NYSE: ARIA) | Delayed: 24.94 -0.15 (0.6%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.09 | 52 Week High | $14.34 | |||
| Open | $24.94 | 52 Week Low | $4.37 | |||
| Day High | $24.94 | P/E | N/A | |||
| Day Low | $24.94 | EPS | $-1.45 | |||
| Volume | 14 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 152.20 +17.03 (12.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $135.17 | 52 Week High | $65.46 | |||
| Open | $146.94 | 52 Week Low | $47.97 | |||
| Day High | $153.50 | P/E | 103.54 | |||
| Day Low | $144.90 | EPS | $1.47 | |||
| Volume | 32,761,916 | |||||
